Literature DB >> 9665488

Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast.

J H Lichy1, M Zavar, M M Tsai, T J O'Leary, J K Taubenberger.   

Abstract

Microdissection of histologically identifiable components from formalin-fixed, paraffin-embedded tissue sections allows molecular genetic analyses to be correlated directly with pathological findings. In this study, we have characterized loss of heterozygosity (LOH) at chromosome 11p15 at different stages of progression in microdissected tumor components from 115 ductal carcinomas of the breast. Microdissected foci of intraductal, infiltrating, and metastatic tumors were analyzed to determine the stage of progression at which LOH at 11p15 occurs. LOH was detected in 43 (37%) of 115 cases. Foci of intraductal carcinoma could be microdissected from 85 cases, of which 30 (35%) showed LOH at some stage of progression. LOH was detected in the intraductal component in 26 of these 30 cases. Interstitial deletions were characterized by using a panel of 10 highly polymorphic markers. The smallest region of overlap (SRO) for LOH at 11p15 was bounded by the markers D11S4046 and D11S1758. LOH at 11p15.5 showed no correlation with estrogen receptor status, the presence of positive lymph nodes, tumor size, histological grade, or long-term survival. We conclude that 11p15 LOH usually occurs early in breast cancer development but less frequently does not develop until the infiltrating or metastatic stages of tumor progression.

Entities:  

Mesh:

Year:  1998        PMID: 9665488      PMCID: PMC1852963          DOI: 10.1016/S0002-9440(10)65568-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Deletion mapping of chromosome 11 in carcinoma of the bladder.

Authors:  M E Shaw; M A Knowles
Journal:  Genes Chromosomes Cancer       Date:  1995-05       Impact factor: 5.006

2.  Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer.

Authors:  G Bepler; M A Garcia-Blanco
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

3.  Frequent loss of heterozygosity at 11p loci in testicular cancer.

Authors:  R C Smith; D B Rukstalis
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450

4.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

5.  Physical mapping of 3 candidate tumor suppressor genes relative to Beckwith-Wiedemann syndrome associated chromosomal breakpoints at 11p15.3.

Authors:  E Redeker; M Alders; J M Hoovers; C W Richard; A Westerveld; M Mannens
Journal:  Cytogenet Cell Genet       Date:  1995

6.  Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3.

Authors:  M Negrini; D Rasio; G M Hampton; S Sabbioni; S Rattan; S L Carter; A L Rosenberg; G F Schwartz; Y Shiloh; W K Cavenee
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

7.  The CEPH consortium linkage map of human chromosome 11.

Authors:  M Litt; P Kramer; E Kort; P Fain; S Cox; D Root; R White; J Weissenbach; H Donis-Keller; R Gatti
Journal:  Genomics       Date:  1995-05-01       Impact factor: 5.736

8.  Occasional loss of constitutive heterozygosity at 11p15.5 and imprinting relaxation of the IGFII maternal allele in hepatoblastoma.

Authors:  M Montagna; C Menin; L Chieco-Bianchi; E D'Andrea
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis.

Authors:  R Winqvist; G M Hampton; A Mannermaa; G Blanco; M Alavaikko; H Kiviniemi; P J Taskinen; G A Evans; F A Wright; I Newsham
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

10.  Correlation of loss of heterozygosity at 11p with tumour progression and survival in non-small cell lung cancer.

Authors:  K M Fong; P V Zimmerman; P J Smith
Journal:  Genes Chromosomes Cancer       Date:  1994-07       Impact factor: 5.006

View more
  9 in total

1.  The long and short of chromosome 11 in breast cancer.

Authors:  I F Newsham
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

2.  Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas.

Authors:  C Washington; F Dalbègue; F Abreo; J K Taubenberger; J H Lichy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

3.  CD81 is a candidate tumor suppressor gene in human gastric cancer.

Authors:  Tae-Hyoung Yoo; Byung-Kyu Ryu; Min-Goo Lee; Sung-Gil Chi
Journal:  Cell Oncol (Dordr)       Date:  2012-12-21       Impact factor: 6.730

4.  Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma.

Authors:  Xiaobing Chen; Xinguang Cao; Wenjie Dong; Suxia Luo; Zhenhe Suo; Yinchun Jin
Journal:  Dig Dis Sci       Date:  2009-10-03       Impact factor: 3.199

5.  Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression.

Authors:  K Kittiniyom; K M Gorse; F Dalbegue; J H Lichy; J K Taubenberger; I F Newsham
Journal:  Breast Cancer Res       Date:  2001-02-12       Impact factor: 6.466

Review 6.  TIP30: A Novel Tumor-Suppressor Gene.

Authors:  Xin Yu; Zheng Li; William K K Wu
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

7.  The role of microsatellite instability at chromosome 11p15.5 in the progression of breast ductal carcinoma.

Authors:  Dong-Ja Kim; Ji-Young Park; Myung-Hoon Lee; Yoon-Kyung Sohn
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

8.  CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.

Authors:  Pamela S Larson; Benjamin L Schlechter; Chia-Lin King; Qiong Yang; Chelsea N Glass; Charline Mack; Robert Pistey; Antonio de Las Morenas; Carol L Rosenberg
Journal:  BMC Cancer       Date:  2008-03-06       Impact factor: 4.430

9.  PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.

Authors:  Xiaoqi Wang; Guangyuan Li; Sanjay Koul; Rieko Ohki; Matthew Maurer; Alain Borczuk; Balazs Halmos
Journal:  Oncotarget       Date:  2015-04-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.